Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 20200904062030
Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.
The most recent report by the National Health and Morbidity
Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with
consistent, unrelenting efforts by stakeholders and policymakers, the figures
for NCDs continue to climb.
MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in
the country and to obtain his thoughts on the ramifications of the findings.
On 18 July 2020, the Malaysian Endocrine and Metabolic Society (MEMS) collaborated with MIMS Education and was supported by Abbott Nutrition to bring the webinar entitled Taking A1ction Now to HCPs, including doctors and pharmacists. The webinar discussed the issues of type 2 diabetes mellitus (T2DM) patients being prone to severe COVID-19 infection and their difficulties in coping with nutrition aspects during the pandemic as well as the role of diabetes-specific nutrition in ensuring T2DM patients thrive during this challenging period.
Chronic heart failure (CHF) is a significant public health concern, affecting at least 26 million individuals worldwide.1 In this case study, Professor Dr Chee Kok Han and Dr Nur Asyikin share their clinical experience running the Heart Failure Frequent Flyer Programme – an initiative between HTAR and UMMC. The Programme enrols CHF patients who had been hospitalised for HF at least twice over the past 12 months and diagnosed with New York Heart Association (NYHA) class II–IV.2
CHF is a frequent cause of hospitalisation at HTAR – a total of 1,140 patients were admitted for CHF between April 2017 and April 2018, with a mean length of stay of 8.2 days. In addition to causing high mortality, hospitalisation for HF (HHF) also places a significant financial burden on patients and the healthcare system. Notably, frequent hospitalisation strongly predicts mortality among patients with CHF – approximately 93% of CHF patients treated at HTAR have recent histories of recurrent admission to the hospital for worsening HF.
The Heart Failure Frequent Flyer Programme was set up with the principal goal of reducing hospitalisation in patients with CHF to improve functional status, quality of life (QoL) and cost of care.The Programme is conducted via a holistic and multidisciplinary approach, incorporating a dedicated HF team (consisting of clinical specialists, clinical pharmacists, HF nurses, dietitian and cardiac rehabilitation team), pharmacist-led patient counselling sessions, as well as nurse-led telemonitoring and SOS walk-in services.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.